Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHARMS: Shu Bi Ning for Active Rheumatoid Arthritis
NCT07627893Phase 3Recruiting
- Sponsor
- Singapore General Hospital
- Start
- Jun 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) (2 arms), sponsored by Singapore General Hospital. Primary endpoint: American College of Rheumatology 20% improvement criteria at 8 weeks. Started Jun 2026; status: recruiting.
02
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07627893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07627893.